It is now known that progenitor stem cells are present and neurogenesis can occur in the spinal cord.
Several models of spinal cord injury have demonstrated neurogenesis after injury.
In vitro studies show that endothelin B receptor agonist, PMZ-1620 (Sovateltide), treatment enhances neurogenesis and neuronal re-networking following spinal cord injury.
In vivo studies show that PMZ-1620 (Sovateltide) significantly improves motor function recovery after spinal cord injury in rat.
Clinical stage – Phase I (CTRI/2016/11/007509) completed; Phase II (NCT04054414) ongoing
Spinal Cord Injury(PMZ-1620 (Sovateltide))